{
    "2018-05-25": [
        [
            {
                "time": "2018-05-25",
                "original_text": "After Hours Most Active for May 25, 2018: ABBV, KR, QQQ, IBM, V, CPE, LOW, SBUX, QCOM, TXN, CELG, INTC",
                "features": {
                    "keywords": [
                        "Most Active",
                        "ABBV",
                        "KR",
                        "QQQ",
                        "IBM",
                        "V",
                        "CPE",
                        "LOW",
                        "SBUX",
                        "QCOM",
                        "TXN",
                        "CELG",
                        "INTC"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "retail",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-25",
                "original_text": "AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Imbruvica",
                        "Phase III",
                        "Study",
                        "Meets",
                        "Primary",
                        "Endpoint"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-25",
                "original_text": "AbbVie’s Imbruvica’s Phase III Study Meets Primary Endpoint",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Imbruvica",
                        "Phase III",
                        "Study",
                        "Meets",
                        "Primary",
                        "Endpoint"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-25",
                "original_text": "Analyzing Ionis’s Q1 Revenue Streams",
                "features": {
                    "keywords": [
                        "Ionis",
                        "Q1",
                        "Revenue",
                        "Streams"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}